mark_alles_celgene

Mark Alles is new chief executive of Celgene

pharmafile | January 12, 2016 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing Celgene, Mark Alles 

Celgene president and chief operating officer Mike Alles has been promoted to the top job after an executive restructure at the biotech firm.

Alles will be promoted to chief executive, while former chief exec Bob Hugin will serve as executive chairman. Hugin will continue to lead the board of directors and manage the strategic direction of the company.

During Hugin’s nearly 17 years of managerial leadership, Celgene has achieved unprecedented growth and produced outstanding results. He says: “I am excited for the opportunity to continue to significantly impact the lives of patients through advancing key strategic initiatives. The elevation of exceptional leaders like Mark, Jackie and Scott will strengthen our organisation and energise our operations allowing us to more fully realize our incredible potential, both benefiting Celgene and the patients that we serve.”

Alles is a three-decade industry veteran. As president and chief operating officer, Mark built and led Celgene’s haematology and oncology franchise, including leading the global launches of Revlimid (lenalidoimde) and Pomalyst (pomalidomide) and the acquisitions and integrations of Pharmion and Abraxis BioSciences.

In other boardroom moves, Jacqualyn Fouse will be promoted to president and chief operating officer, while Scott Smith, who is president of immunology and inflammation, will assume an expanded leadership role.

Jacqualyn Fouse joined Celgene in 2010 as chief financial officer and has excelled as both the leader of Celgene’s finance department and in her current role as president of Celgene’s haematology and oncology franchise. She will now focus on further enhancing Celgene’s commitment to operational excellence, driving exceptional performance across Celgene’s franchises and functions. Reporting to Jackie in this role will be Celgene’s corporate operational functions as well as the haematology and oncology and inflammation and immunology franchises.

Scott Smith will also be chair of Celgene’s global management committee, and will be responsible for the effective coordination of Celgene’s operational and strategic imperatives. He joined Celgene in 2008 and will continue to be responsible for building and leading Celgene’s inflammation and immunology franchise.

“Mark is an extraordinary leader, whose knowledge of our business and commitment to patients have propelled the organisation to incredible success,” Bob Hugin says. “Jackie’s strong leadership and strategic capabilities set the standard for our organisation. Scott is responsible for building our I&I franchise and has consistently delivered exceptional results. Mark’s, Jackie’s and Scott’s wealth of industry and company experience, judgment and strategic vision are invaluable as we continue to lead the company into the future.”

Related Content

celgene_building

NICE recommends Celgene’s REVLIMID for multiple myeloma

NICE has issued a Final Appraisal Document (FAD) recommending Celgene’s REVLIMID (lenalidomide) as maintenance treatment …

NICE opts to reject Celgene’s Revlimid for newly diagnosed multiple myeloma after an autologous stem cell transplant

It has emerged that NICE has opted to reject Celgene’s Revlimid (lenalidomide) for the maintenance …

celgene_building

NICE recommends Celgene’s Revlimid combo for follicular lymphoma

NICE has chosen to recommend Celgene’s Revlimid (lenalidomide) for use on the NHS, it has …

Latest content